



Weekly news for faculty, staff and students from
the **Indiana University School of Medicine**

Features

Past Issues

Subscribe

Contact

October 16, 2014



Late faculty pioneer gifts \$8.5 million to
benefit IUSM heart research,
education



Charter celebration welcomes Scientific
Toasters Club to school, campus

Research News

IU startup Anagin wins NIH business innovation grant, BioCrossroads venture competition

Researchers develop new cells meant to form blood vessels, treat peripheral artery disease

Faculty and Staff News

Adams named Indiana State Department of Health commissioner

Turrentine named John W. Brown Chair in Cardiothoracic Surgery

Student Showcase

Students sought for 2014 Leadership Day

Opportunities

Stark Neurosciences Research Institute seeks executive director

Access drug development services through the Indiana CTSI and Covance

Campus flu shots now available

News to Use

Ebola: An Urgent Conversation About Ethics, Law, Public Health and Practice

IU hosted public forum on Ebola video online

IUSM grants and awards report -- September 2014

'Sound Medicine'

Reshaping medical education, working towards a treatment for Ebola, and more

Events

10/21/2014

2014 Steven C. Beering Award Lecture

10/20/2014

Holland Lecture to focus on cancer genetics (IU Bloomington)

10/21/2014

Corcoran Lecture: Collaboration as the Key to Healthcare Excellence (IUSM-Evansville)

10/22/2014

The Fall of Icarus: mental health and burnout in medicine

10/23/2014

Bioethics presentation on stem cell therapies

10/24/2014

Fifth Annual Gladstein Professor Lecture

10/28/2014

'CODE BLACK' documentary screening

[View more events »](#)

Research News

IU startup Anagin wins NIH business innovation grant, BioCrossroads venture competition

Anagin, a company launched by two IU scientists to develop a first-of-its-kind treatment to battle post-traumatic stress disorder, was recently named the recipient of **a \$692,706 Phase I Small Business Innovation**

Research grant from the National Institutes of Health as well as the **winner of the third annual BioCrossroads New Venture Competition** on Oct. 14

The company emerged from six finalists Tuesday to receive a \$25,000 cash prize as part of a contest held in conjunction with the 2014 Indiana Life Sciences Summit at the JW Marriott hotel in Indianapolis. The winner also receives business planning and early strategic support from the Indiana Seed Fund II, as well as the opportunity for more exposure by making a presentation to the fund's investment committee.

Co-founded by Anantha Shekhar, a professor of psychiatry, pharmacology and neurobiology at the IU School of Medicine; and Yvonne Lai, a senior scientist in the Department of Psychological and Brain Sciences at IU Bloomington, Anagin is developing drugs that directly inhibit the brain mechanisms that cause PTSD, but without the debilitating side effects that come with current treatments. Those include agitation, irritability, sexual dysfunction, drowsiness, memory and motor skill problems and addiction,

"Since (our) drugs do not directly block the normal brain chemical message mechanisms, they will not cause sedation, memory problems and motor difficulties such as balance, walking and driving. So we think the effectiveness of these medications will be much greater," said Shekhar, associate vice president for university clinical affairs at IU and director of the **Indiana Clinical and Translational Sciences Institute**. "Our team is extremely pleased to win such an honor, especially given the rigorous evaluation process and the promise held by the other finalist companies as well. This award will play a key role in helping to advance our technology development and offers additional avenues to reinforce our strategies as we prepare to enter the market."

One in seven Americans -- in cases that range from child abuse, domestic abuse, and sexual assault to the trauma faced by soldiers, police, and firefighters -- will battle post-traumatic stress disorder at some point in their lives. Current medicines work for only half of the 24.4 million Americans who suffer PTSD at any given time and they see only 30 to 60 percent improvement in their symptoms, he added.

Along with the NIH and Biocrossroads funds, Anagin will receive \$50,000 in matching funds from **Elevate Ventures**, a nonprofit organization that provides state dollars to promising, early-stage entrepreneurs who have received funding through small business grants.

For more on Anagin, visit the **IUPUI Newsroom website**.

BACK TO TOP ▲

Researchers develop new cells meant to form blood vessels, treat peripheral artery disease

An international team, led by scientists at the IU School of Medicine, recently reported in the journal Nature Biotechnology that they have developed a technique to jump-start the body's systems for creating blood vessels, opening the door for potential new treatments for diseases whose impacts include amputation and blindness.

The researchers are targeting new therapies for illnesses such as peripheral artery disease, a painful leg condition caused by poor blood circulation. The disease can lead to skin problems, gangrene and sometimes amputation.

Although body has cells that specialize in creating and repairing blood vessels and creating new ones, these cells can lose their ability to proliferate into new blood vessels as patients age or develop diseases, such as peripheral arterial disease. However, study researchers now report they have developed a potential new therapy through the use of normal adult cells that have been "coaxed" via laboratory techniques into

reverting into the more primitive stem cells that can produce most types of bodily tissue.

Overcoming another hurdle that has been faced by scientists in the field, the research team found that the cord-blood-like endothelial colony-forming cells grown in laboratory tissue culture expanded dramatically, creating 100 million new cells for each original cell in a little less than three months.

The leader of the research team is Mervin Yoder, M.D., Richard and Pauline Klingler Professor of Pediatrics at IU. Additional IU researchers on the study are Nutan Prasain, Man Ryul Lee, Sasidhar Vemula, Jonathan Luke Meador, Momoko Yoshimoto, Michael J. Ferkowicz, Alexa Fett, Manav Gupta, Brian M. Rapp, Mohammad Reza Saadatzadeh, Michael P. Murphy and Hal E. Broxmeyer.

For more information, visit the [IUSM Newsroom website](#).

[BACK TO TOP ▲](#)

Faculty and Staff News

Adams named Indiana State Department of Health commissioner

Jerome Adams, M.D., MPH, assistant professor of clinical anesthesia at IU School of Medicine, was named commissioner for the Indiana State Department of Health Oct. 8 by Gov. Mike Pence.

“His public service and academic achievements make Dr. Jerome Adams the ideal candidate to serve in this role,” Pence said. “I am confident that he will bring his extensive health care experience and insights to the Indiana State Department of Health and continue the great work of the agency as they strive to improve the health of all Hoosiers.”

Dr. Adams also serves as a staff anesthesiologist at Eskenazi Health, where he is chair of the Pharmacy and Therapeutics Committee. Previously, he served as a general anesthesiologist at Ball Memorial Hospital in Muncie, Ind., and as a physician rapid responder at Indianapolis Orthopaedic Hospital.

Dr. Adams has been a member of several professional organizations, including the Indiana Society of Anesthesiologists, the American Medical Association and the National Medical Association; and he serves as chair of the Professional Diversity Committee for the American Society of Anesthesiologists. He is on the executive committee for the Indiana State Medical Association and has a great deal of research experience, including working under Nobel Prize winner Thomas Cech, Ph.D.

He is a graduate of the University of Maryland, where he earned his undergraduate degree; the University of California, Berkeley, where he earned his Master of Public Health; and the IU School of Medicine.

Dr. Adams will assume his new role Oct. 22.

[BACK TO TOP ▲](#)

Turrentine named John W. Brown Chair in Cardiothoracic Surgery

Mark W. Turrentine, M.D., has been named the first holder of the John W. Brown Chair in Cardiothoracic Surgery, effective Oct. 1.

Dr. Turrentine's new faculty title will be John W. Brown Professor of Cardiothoracic Surgery. He will retain his current title of professor of surgery.

Dr. Turrentine joined the IU School of Medicine in 1991 as an assistant professor of surgery. He was named an associate professor of surgery in 1998 and a professor of surgery in 2004. He has also served as the director of pediatric cardiac transplantation at Riley Hospital for Children at IU Health since 1991. He is also currently the interim chief of cardiothoracic surgery at the IU School of Medicine.

Dr. Turrentine holds a medical degree from the University of Kansas School of medicine and an bachelor's degree in biology and chemistry from Southwestern College. He served an internship in general surgery at the University of Kansas, followed by residencies in general surgery and cardiothoracic surgery at the University of Kansas and IU School of Medicine, respectively. He also served fellowships in cardiothoracic surgery at Texas Heart Institute and pediatric cardiac surgery and cardiac and pulmonary transplantation at the IU School of Medicine.

The John W. Brown Chair in Cardiothoracic Surgery was established in 2013 by multiple donors in honor of the long-time chief of cardiothoracic surgery. It is the intent of the donors that the holder of the chair will be a faculty member in the Division of Cardiothoracic Surgery, Department of Surgery, at the IU School of Medicine.

[BACK TO TOP ▲](#)

Student Showcase

Students sought for 2014 Leadership Day

IUSM student are sought to register for the 2014 Leadership Day from 8:30 a.m. to 3:30 p.m. Saturday, Oct. 25, in Fairbanks Hall, Room 1110-1112.

This free event includes speakers and team building activities designed to develop medical students' leadership skills. Speakers include Stephen Bogdewic Ph.D., executive vice dean and Dr.

George W. Copeland Professor of Family Medicine; Antwione Haywood, Ph.D., an academic specialist and assistant dean of medical student affairs; and Carla and Marc Drizin of **Ignite**, a human resources consulting firm in Carmel, Ind. Alice Chen of the Teacher-Leader Advocacy Committee will also hold an informal Q-and-A session.

The event will conclude with a service project at Riverside Park from 1:15 to 3:15 p.m.

Breakfast and lunch will be provided. For more information or to register, [visit the IUSM Medical Student Council's website](#).

This event is presented by the IUSM Medical Student Council with support from the IUPUI Student Organization Grant.

If you have questions, contact Annalise Almdale, vice president of the Medical Student Council, at aalmdale@iupui.edu.

[BACK TO TOP ▲](#)

Opportunities

Stark Neurosciences Research Institute seeks executive director

The IU School of Medicine seeks a visionary academic leader to serve as executive director of the **Stark Neurosciences Research Institute**. The successful candidate will have a strong background in academic leadership, research and teaching. Experience should include evidence of building diverse collaborations and teams, innovative problem-solving, strategic vision-setting and transformational leadership in academic medicine. Candidates should possess an M.D., Ph.D., or M.D./Ph.D. and have a strong, active neuroscience research program.

Neuroscience research has a long history of excellence at the IU School of Medicine. In 2000, Paul Stark and his wife Carole provided the school with a \$15 million bequest to endow a multidisciplinary neurosciences research institute. Their goal was to enable rigorous investigations of normal and abnormal function in the central nervous system using the most advanced technologies and to apply the resulting discoveries to the treatment of devastating neurological disorders. The Stark Neurosciences Research Institute is now home to several highly productive neuroscience research groups focusing on addiction, anxiety, spinal cord and brain injury, motoneuron injury and disease, neuroimmunology and pain. In addition, it coordinates two internationally recognized research centers funded by the National Institutes of Health focusing on: (1) Alzheimer's disease and (2) alcoholism. Partnering with industry, SNRI interacts with **Eli Lilly and Company** focusing on the development of drugs for neurological disorders at their headquarters here in Indianapolis, Indiana. In addition, there is a strong program integrating neuromusculoskeletal biology between IUSM researchers and VA investigators at the Richard L. Roudebush VA Research Service.

IUSM has positioned itself to be a leader in the neurosciences through committed resources, supportive leadership and partnerships, and the addition of two new buildings. The IU Neurosciences Research building, which opened in the spring of 2014, is home to IUSM scientists conducting studies in fields such as neurotrauma, dementias, neurodegenerative diseases, epilepsy, addiction and pain. The 138,000-square-foot research building adjoins, and on three floors is connected to, Goodman Hall, the ambulatory care and imaging facility of the **IU Health Neuroscience Center**. Co-located in the IU Health Neuroscience Center are colleagues in Neurology, Neuroimaging, Neurosurgery, Physical Medicine and Rehabilitation, and Psychiatry. The resulting 408,000-square-foot center provides a modern, expertly designed space for collaboration and innovation by physicians and researchers that is rare, if not unique. It also offers important opportunities for educating future scientists and physicians.

IUSM has nine campuses across the state, educating the nation's second-largest medical student body. Our clinical, research and education partners (most within walking distance) include IU Health, Eskenazi Health and the Richard L. Roudebush VA Medical Center. The main campus is in Indianapolis, the 12th largest city in the United States, which is growing and thriving economically due to a strong corporate base anchored by the life sciences. Indiana is home to one of the largest concentrations of health sciences companies in the nation, which contribute over \$44 billion annually to its economy. The vibrant downtown is a bustling commercial center, entertainment destination and residential neighborhood. The expanding residential base is driven by rich amenities and quality of life – the city is home to a variety of professional sports, arts venues and outdoor recreation areas.

Candidates interested in this leadership opportunity should **visit the IU School of Medicine's faculty jobs website** to apply. Please include one PDF containing the following: (1) a short letter of interest noting key leadership experiences and/or approaches and (2) a curriculum vitae. The priority application review

deadline is Monday, Nov. 24.

The letter should be addressed to search committee co-chairs:

Tatiana Foroud, Ph.D.

P. Michael Conneally Professor of Medical and Molecular Genetics

Mary Dankoski, Ph.D.

Executive Associate Dean for Faculty Affairs and Professional Development

Indiana University is an equal opportunity and affirmative action employer. All qualified applicants will receive consideration for employment without regard to race, color, ethnicity, religion, age, sex, sexual orientation or identity, national origin, disability status, or protected veteran status. This institution is also a provider of ADA services.

[BACK TO TOP ▲](#)

Access drug development services through the Indiana CTSI and Covance

The Molecular Therapeutics Program, a part of the Indiana Clinical and Translational Sciences Institute, has established a service agreement with Covance, Inc., to support early drug discovery through in vivo assessment.

The **Indiana CTSI** is a National Institutes of Health-funded collaboration of IU, Purdue University and the University of Notre Dame that facilitates the translation of scientific discoveries in the lab into new patient treatments. **Covance, Inc.** is one of the world's largest and most comprehensive drug development services companies.

The Indiana CTSI and Covance **formed an alliance last year to conduct early clinical trials** on behalf of biotechnology and pharmaceutical companies at clinical research facilities managed by the Indiana CTSI at the IU School of Medicine in Indianapolis -- as well as Covance's clinical research unit in Evansville. Early phase clinical research includes trials in which investigational new drugs are administered to humans for the first time.

The list of drug development services available through the Indiana CTSI-Covance alliance include Ames toxicity screening; Oral Gavage Pilot Toxicity Study; Toxicity and Toxicokinetic study; hERG; Screening Package (Membrane Permeability and P group Assessment, Metabolic Stability, and Rat PK); Membrane Permeability and P-group Assessment; Metabolic Stability; Rat PK; Rat Cassette PK; Dose Formulation Optimization.

These services are available to all three universities partners affiliated with the Indiana CTSI: IU, Purdue and Notre Dame.

For more information about these services, including pricing estimates, contact Padma Portonovo, project manager for the IUSM-Indiana CTSI Industry Collaboration Portal, at pportono@iupui.edu.

[BACK TO TOP ▲](#)

Campus flu shots now available

IUPUI Campus Health is currently offering free flu shots to IUSM faculty, staff, house staff and students during the 2014-2015 flu season.

Faculty, staff, house staff and students can obtain a flu shot at Campus Health (Coleman Hall, Suite 100) or a Campus Health outreach flu vaccination clinic. Students only can also obtain a flu shot at Campus Center Student Health. No appointment is necessary. All individuals must present a valid university picture ID to obtain a flu shot. Students will be asked to present a health insurance card but will be able to receive a free flu shot regardless of whether or not they have health insurance.

IUSM faculty, staff, house staff and students who provide clinical care to IU Health or Eskenazi Health patients, perform clinical research at IU Health or Eskenazi Health, or whose primary office is in an IU Health or Eskenazi Health are again required to receive a flu vaccine this flu season. The deadline for receiving the vaccine is Nov. 21.

IUPUI Campus Health is charged with tracking flu shot compliance for IUSM house staff and students. Flu shots received from Campus Health will automatically be tracked. House staff and students who opt to receive flu vaccination from IU Health, a personal physician or elsewhere must submit their flu shot consent form to IUPUI Campus Health at healthsv@iupui.edu or via fax at 317-278-6929.

 A complete list of flu outreach clinics, including sites at the IU School of Medicine, is online.

[BACK TO TOP ▲](#)

News to Use

Ebola: An Urgent Conversation About Ethics, Law, Public Health and Practice

"Ebola: 'Over There'... Now 'Over Here' -- An Urgent Conversation About Ethics, Law, Public Health and Practice," will be from 1:30 to 3:30 p.m. Friday, Oct. 24, in the IU Robert H. McKinney School of Law, Room 375.

The initial outbreak of Ebola Virus Disease in West Africa presented many ethical, legal, logistical and clinical challenges for first responders, clinicians, politicians and researchers. These challenges have been magnified now that the virus has crossed the Atlantic. A group of experts in the ethical, legal, public health and clinical care implications will discuss several key issues facing patients, practitioners and the public. An open dialogue will follow short presentations from each participant. Discussants include:

- Eric M. Meslin, Ph.D., director of the IU Center for Bioethics, associate Dean and Professor of Bioethics at the IU School of Medicine and professor of law and bioethics at the IU Robert H. McKinney School of Law
- Chad Priest, assistant dean for operations and community partnerships at the IU School of Nursing and co-director of the Disaster Medicine Fellowship and adjunct assistant professor of emergency medicine at the IU School of Medicine
- Ross D. Silverman, professor and acting chair of health policy and management at the IU Richard M. Fairbanks School of Public Health and professor of public health and law at the IU Robert H. McKinney School of Law
- Nicolas P. Terry, Hall Render Professor of Law and director of the Hall Center for Law and Health at the IU Robert H. McKinney School of Law

This is a free event, but [registration](#) is required. Light refreshments will be served.

For more information, visit the [IU Robert H. McKinney School of Law's website](#).

[BACK TO TOP ▲](#)

IU hosted public forum on Ebola video online

In response to the current outbreak of the Ebola virus in West Africa, IU recently presented an educational forum to raise awareness on campus and in the community, and to highlight IU's connections in the region, especially in Liberia.

The program, which took place Oct. 13 in Whittenberger Auditorium in the Indiana Memorial Union in Bloomington, Ind., discussed panelist on the medical, public health and physiological aspects of the Ebola virus; provided a cultural context for the response in Liberia; addressed methods for controlling the outbreak; and considered next steps in global public health.

Panelists included Joshua Mugele, associate professor of clinical emergency medicine at the IU School of Medicine, and Chad Priest, assistant dean for operations and community partnerships at the IU School of Nursing. Mugele and Priest are co-directors of the Indiana University Disaster Medicine Fellowship and founded the Dr. Sam Brisbane Fund, a fundraising campaign to support John F. Kennedy Hospital in Monrovia, Liberia, and named for a Liberian doctor and colleague who died from Ebola. ([Dr. Mugele's experiences at JFK Hospital were recently recounted in a segment on NPR.](#))

Other participants were Charles Reafsnyder, a retired associate vice president for international affairs at IU, and Ruth Stone, the Laura Bolton professor of folklore and ethnomusicology at IU Bloomington and a scholar of Liberian music, culture and performance. Michael Reece, associate dean of the IU School of Public Health-Bloomington, moderated the discussion.

The forum is available via an [archived video stream](#).

[BACK TO TOP ▲](#)

IUSM grants and awards report -- September 2014

IU School of Medicine researchers earned about \$7.5 million in grants and awards -- excluding commercial projects -- in September 2014:

Investigator	Sponsor	Type	Project Title	Begin Date	End Date	Awarded Dollars
Jeffrey O. Anglen, M.D.	Johns Hopkins University	New	Supplemental perioperative oxygen to reduce surgical site infection after high energy fracture surgery	7/11/2014	9/29/2014	\$16,000
Naga P. Chalasani, M.D.	National Institute of Diabetes,	Renewal	Nonalcoholic Steatohepatitis Clinical Research	8/1/2014	6/30/2015	\$163,837

	Digestive and Kidney		Network (NASH CRN) - IU Clinical Center			
Wilbert A. Derbigny, Ph.D.	National Institute Allergy and Infectious Diseases	New	The role of TLR3 signaling in Chlamydia caused urogenital pathology	9/1/2014	8/31/2015	\$385,091
Linda A. DiMeglio, M.D.	Benaroya Research Institute at Virginia Mason	New	TIDAL - Inducing Remission in New Onset T1DM with Alefacept (Amevive)	5/1/2014	12/31/2014	\$45,930
A. Keith Dunker, Ph.D.	National Library of Medicine	Renewal	Pacific Symposium on Biocomputing	9/5/2014	7/31/2015	\$20,000
Robert M. Einterz, M.D.	Abbvie Foundation	New	Academic Model Providing Access to Healthcare (AMPATH) 2014	7/1/2014	6/30/2015	\$100,000
David A. Flockhart, M.D., Ph.D.	National Human Genome Research Institute	New	Embedding pharmacogenotyping in an integrated health system for the underserved	9/5/2014	6/30/2015	\$750,000
Maria B. Grant, M.D.	Research Foundation-State University New York	New	Regulation and function of the matricellular protein CCN-1 in ischemic retinopath	12/1/2013	11/30/2014	\$95,389
David M. Haas, M.D.	Rti International	New	Pregnancy as a window to future cardiovascular health	8/1/2014	4/30/2015	\$312,039
Xiaoming Jin, M.D., Ph.D.	Citizens United For Research In Epilepsy	New	Targeting High Mobility Group Box-1 signaling for preventing posttraumatic epileptogenesis	9/1/2014	8/31/2015	\$85,000
Melissa A. Kacena, Ph.D.	U.S. Army Research Office	New	Effects of spaceflight and novel treatments on bone regeneration - in vitro studies	9/15/2014	9/14/2016	\$145,015
Mark H. Kaplan, Ph.D.	University of Notre Dame	New	Engineering heterobivalent inhibitors for specific inhibition of mast cell degranulation	7/15/2014	6/30/2015	\$104,625

Debomoy K. Lahiri, Ph.D.	Purdue University	New	Exploring FOXO signaling in promoting neurodegeneration in Alzheimer Disease	7/1/2014	6/30/2015	\$43,090
Zhigang Lei, Ph.D.	American Heart Association-Greater Midwest Affiliate	New	Regulation of potassium channels by calpain in poststroke seizures and epilepsy	7/1/2014	6/30/2015	\$71,500
Lang Li, Ph.D.	National Institute of General Medical Sciences	New	A translational bioinformatics approach in the drug interaction research	9/1/2014	5/31/2015	\$340,872
Naikui Liu, M.D., Ph.D.	Indiana State Department of Health	New	Activation of cPLA2 and mitochondrial dysfunction in spinal cord injury.	7/1/2014	6/30/2016	\$120,000
Yan Liu, Ph.D.	Alexs Lemonade Stand Foundation	New	Targeting PRL2 in Pediatric Acute Myeloid Leukemia	9/2/2014	9/1/2015	\$20,000
Patrick J. Loehrer, M.D.	National Cancer Institute	Renewal	Indiana University Melvin and Bren Simon Cancer Center Support Grant	9/1/2014	8/31/2015	\$1,559,793
Omkar N. Markand, M.D.	Indiana Family and Social Services Administration	Renewal	Epilepsy Clinic and Services	7/1/2014	6/30/2016	\$700,000
Thomas W. McAllister, M.D.	Dartmouth College	New	Effect of biomechanical force exposure on cognition and brain activation in traumatic brain injury	7/1/2013	12/31/2014	\$177,853
Raghu G. Mirmira, M.D., Ph.D.	American Physiological Society	New	Regulation of islet beta cell inflammation by the DHS/eIF5A Pathway	9/1/2014	8/31/2015	\$28,300
Sharon M. Moe, M.D.	National Institute Of Diabetes, Digestive and Kidney	New	Genetic risks for cardiovascular events in ESRD patients from the EVOLVE study.	8/25/2014	6/30/2015	\$351,886

Jean P. Molleston, M.D.	University of Michigan	New	Childhood Liver Disease Research and Education Network Data Coordinating Center	6/1/2014	5/31/2015	\$20,243
Kenneth R. Olson, Ph.D.	National Science Foundation	New	Reactive sulfide species: ubiquitous and primordial signaling molecules	8/1/2014	7/31/2016	\$299,999
Frederick J. Rescorla, M.D.	Riley Children's Foundation	Renewal	Chairman of Surgery	7/1/2014	6/30/2015	\$30,000
Robert S. Tepper, M.D., Ph.D.	Riley Children's Foundation	Renewal	Mary Agnus Kennedy Chair	7/1/2014	6/30/2015	\$73,997
Jeffrey B. Travers, M.D., Ph.D.	National Institute on Aging	New	Wounding therapy and photocarcinogenesis	9/1/2014	4/30/2015	\$319,800
Kathleen T. Unroe, M.D.	National Institute on Aging	New	Delivering hospice and palliative care services to nursing home patients	9/1/2014	5/31/2015	\$160,572
Frederick W. Unverzagt, Ph.D.	National Institute on Aging	New	Cognitive and aerobic resilience for the brain	8/1/2014	4/30/2015	\$547,328
Claire E. Walczak, Ph.D.	National Institute of General Medical Sciences	New	Control of microtubule dynamics for spindle assembly and chromosome segregation	7/1/2014	8/31/2015	\$416,480
James C. Williams, Ph.D.	NIH Office of the Director	New	SkyScan 1176 Micro CT System	9/15/2014	9/14/2015	\$382,900

[BACK TO TOP ▲](#)

